US equities |
SPCX $167.10 ▲+5.12% NVDA $236.34 ▲+1.02% MU $1,064.36 ▼-0.98% TSLA $378.45 ▲+2.12% MSFT $525.21 ▲+1.48% SNDK $1,709.43 ▼-0.61% INTC $117.31 ▼-1.69% META $744.43 ▲+2.25%
FinancialContent

Bristol-Myers Squibb (NY:BMY)

59.03 -2.12 (-3.47%)
Delayed Quote Updated: 12:25 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
93 94 Next >
News headline image
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet... 
Via MarketMinute
News headline image
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
J&J’s Investigational Plaque Psoriasis Drug Outperforms Bristol Myers’ Sotyktu In Study ↗
Via Stocktwits
News headline image
Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
From Bristol Myers Squibb
Via Business Wire
News headline image
Why Replimune Stock Plummeted by Almost 40% Today ↗
The fate of a once-promising cancer treatment now looks uncertain at best. 
Via The Motley Fool
News headline image
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials ↗
Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis. 
Via Benzinga
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Advancing Cancer Research Brings New Hope for Patients Worldwide
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Great High-Yield Dividend Stocks to Buy in September ↗
Quality yields above 6% from three very different market sectors. 
Via The Motley Fool
News headline image
BRISTOL-MYERS SQUIBB CO (NYSE:BMY): A High-Yield Dividend Stock with Strong Profitability ↗
Bristol-Myers Squibb (BMY) offers a compelling 5.22% dividend yield with a strong history of growth, backed by high profitability and an attractive valuation. 
Via Chartmill
News headline image
The Specter of Stagflation: A Looming Threat to Global Markets
The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
News headline image
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
News headline image
The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now ↗
With a 6.2% yield, this high yielder is focused on supporting the innovation that drives the healthcare industry forward. 
Via The Motley Fool
Topics Intellectual Property
News headline image
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy ↗
BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates. 
Via Benzinga
News headline image
S&P 500 Soars to Uncharted Territory: Is the Market Overvalued or Justified by a New Era of Growth?
The S&P 500 index has repeatedly scaled new all-time highs in recent months, a testament to robust corporate earnings and an enduring wave of optimism, largely fueled by advancements in Artificial... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields ↗
 
Via Benzinga
News headline image
Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug ↗
Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results. 
Via Benzinga
News headline image
2 Top Dividend Stocks to Buy With Less Than $50 ↗
These stocks are cheap in more ways than one. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Large-Cap Stocks Worth Your Attention and 1 We Brush Off
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for... 
Via StockStory
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Beating The September Curse–These 10 Stocks Shine While The S&P 500 Stumbles ↗
September is historically the worst month for stocks, but these 10 S&P 500 companies have consistently delivered gains. 
Via Benzinga
Topics Stocks
News headline image
Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease ↗
Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers. 
Via Investor's Business Daily
News headline image
Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Bristol-Myers Squibb (NYSE:BMY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Profitable Stock Worth Investigating and 2 We Turn Down
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
93 94 Next >